Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner

被引:10
作者
Chung, Heekyung [1 ]
Chaudhry, Joy [1 ]
Lopez, Claudia G. [1 ]
Carethers, John M. [1 ,2 ,3 ]
机构
[1] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, San Diego, CA 92103 USA
[3] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
关键词
5-fluorouracil; colorectal cancer; DNA mismatch repair; cyclin E; histone H3; cancer treatment; microsatellite instability; NONPOLYPOSIS COLON-CANCER; NITRO-N-NITROSOGUANIDINE; COLORECTAL-CANCER; MICROSATELLITE-INSTABILITY; GENE-EXPRESSION; CELL-CYCLE; ADJUVANT CHEMOTHERAPY; CARCINOMA-CELLS; CONTINUOUS-INFUSION; FLUOROURACIL;
D O I
10.4161/cbt.10.11.13447
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Several studies indicate that the DNA mismatch repair (MMR) system may trigger cytotoxicity upon 5-fluorouracil (5-FU) recognition, but signaling pathways regulated by MMR in response to 5-FU are unknown. We hypothesize that recognition of 5-FU in DNA by MMR proteins trigger specific signaling cascades that results in slowing of the cell cycle and cell death. Whole human genome cDNA microarrays were used to examine relative signaling responses induced in MMR-proficient cells after 5-FU (5 mu M) treatment for 24 hours. Analysis revealed 43 pathways differentially affected by 5-FU compared to control (p < 0.05), including cyclin and cell cycle regulation involving G(1)-S cell cycle transition, activation of Src, MAP K, p53 and base excision repair. In particular, 5-FU upregulated cyclins E1 and E2 (>= 1.4-fold) and downregulated cdc25C, cyclins B1 and B2, histone H2A, H2B and H3 (<=-1.4-fold) over control. Cell cycle analysis revealed a G(1)/S arrest by 5-FU that was congruent with increased cyclin E and decreased cdc25C protein expression. Importantly, with knockdown of hMLH1 and hMSH2, we observed that decreased histone H3 expression by 5-FU was dependent on hMLH1. Additionally, 5-FU treatment dramatically decreased levels of several histone H3 modifications. Our data suggest that 5-FU induces a G(1)/S arrest by regulating cyclin E and cdc25C expression and MMR recognition of 5-FU in DNA may modulate cyclin E to affect the cell cycle. Furthermore, MMR recognition of 5-FU reduces histone H3 levels that could be related to DNA access by proteins and/or cell death during the G(1)/S phase of the cell cycle.
引用
收藏
页码:1148 / 1157
页数:10
相关论文
共 48 条
[1]
Akiyama Y, 1997, CANCER RES, V57, P3920
[2]
Mismatch repair, G2/M cell cycle arrest and lethality after DNA damage [J].
Aquilina, G ;
Crescenzi, M ;
Bignami, M .
CARCINOGENESIS, 1999, 20 (12) :2317-2325
[3]
Histone modifications and nuclear architecture:: A review [J].
Bartova, Eva ;
Krejci, Jana ;
Harnicarova, Andrea ;
Galiova, Gabriela ;
Kozubek, Stanislav .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2008, 56 (08) :711-721
[4]
Covalent modifications of histones during development and disease pathogenesis [J].
Bhaumik, Sukesh R. ;
Smith, Edwin ;
Shilatifard, Ali .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (11) :1008-1016
[5]
Colorectal cancer prevention and treatment [J].
Boland, CR ;
Sinicrope, FA ;
Brenner, DE ;
Carethers, JM .
GASTROENTEROLOGY, 2000, 118 (02) :S115-S128
[6]
Carethers JM, 2007, FALK SYMP, V158, P72
[7]
Mismatch repair proficiency and in vitro response to 5-fluorouracil [J].
Carethers, JM ;
Chauhan, DP ;
Fink, D ;
Nebel, S ;
Bresalier, RS ;
Howell, SB ;
Boland, CR .
GASTROENTEROLOGY, 1999, 117 (01) :123-131
[8]
Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine [J].
Carethers, JM ;
Hawn, MT ;
Chauhan, DP ;
Luce, MC ;
Marra, G ;
Koi, M ;
Boland, CR .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (01) :199-206
[9]
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer [J].
Carethers, JM ;
Smith, EJ ;
Behling, CA ;
Nguyen, L ;
Tajima, A ;
Doctolero, RT ;
Cabrera, BL ;
Goel, M ;
Arnold, CA ;
Miyai, K ;
Boland, CR .
GASTROENTEROLOGY, 2004, 126 (02) :394-401
[10]
Clarke PA, 2003, CANCER RES, V63, P6855